Policy | September 16, 2025
FDA launches crackdown on deceptive drug advertising
The FDA is beginning rulemaking to close the “adequate provision” loophole
The FDA is beginning rulemaking to close the “adequate provision” loophole
Experts urge early detection & better access to care
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
The development marks an important step in Sigachi's strategic focus on expanding its presence in complex, high-value specialty APIs, aligned with global demand for advanced therapies in rare and chronic disease segments
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The initiative is focused on a problem that continues to plague cancer outcomes in India
Subscribe To Our Newsletter & Stay Updated
